A Reversal for Mediwound Limited Ord (NASDAQ:MDWD) Is Near. The Stock Has Decrease in Shorts

February 15, 2018 - By Marie Mckinney

 A Reversal for Mediwound Limited Ord (NASDAQ:MDWD) Is Near. The Stock Has Decrease in Shorts

The stock of Mediwound Limited Ord (NASDAQ:MDWD) registered a decrease of 9.24% in short interest. MDWD’s total short interest was 123,700 shares in February as published by FINRA. Its down 9.24% from 136,300 shares, reported previously. With 36,400 shares average volume, it will take short sellers 3 days to cover their MDWD’s short positions. The short interest to Mediwound Limited Ord’s float is 1.21%.

The stock increased 2.41% or $0.1 during the last trading session, reaching $4.25. About 13,178 shares traded. MediWound Ltd. (NASDAQ:MDWD) has declined 11.84% since February 15, 2017 and is downtrending. It has underperformed by 28.54% the S&P500.

MediWound Ltd., an integrated biopharmaceutical company, focuses on developing, manufacturing, and commercializing novel therapeutics products in Israel. The company has market cap of $114.95 million. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns. It currently has negative earnings. The firm also develops EscharEx, which is in Phase II clinical trials for the debridement of chronic and other hard-to-heal wounds.

MediWound Ltd. (NASDAQ:MDWD) Ratings Coverage

Among 7 analysts covering MediWound (NASDAQ:MDWD), 7 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. MediWound had 18 analyst reports since August 10, 2015 according to SRatingsIntel. Wells Fargo initiated the stock with “Outperform” rating in Wednesday, August 17 report. Jefferies maintained the stock with “Buy” rating in Tuesday, September 26 report. The firm earned “Outperform” rating on Monday, August 10 by Credit Suisse. Oppenheimer maintained the shares of MDWD in report on Thursday, July 20 with “Buy” rating. The firm has “Buy” rating by Oppenheimer given on Thursday, November 16. SunTrust maintained MediWound Ltd. (NASDAQ:MDWD) on Thursday, November 16 with “Buy” rating. The rating was maintained by Oppenheimer on Friday, December 8 with “Buy”. The rating was maintained by Jefferies with “Buy” on Monday, June 12. SunTrust initiated it with “Buy” rating and $13 target in Wednesday, March 23 report. On Tuesday, June 27 the stock rating was maintained by Oppenheimer with “Buy”.

More notable recent MediWound Ltd. (NASDAQ:MDWD) news were published by: Globenewswire.com which released: “BARDA Upsizes Contract with MediWound and Exercises Option to Fund Further …” on July 19, 2017, also Globenewswire.com with their article: “MediWound Reports Third Quarter 2017 Financial Results” published on November 16, 2017, Globenewswire.com published: “MediWound Ltd. Announces Pricing of $22 Million Public Offering of Ordinary Shares” on September 19, 2017. More interesting news about MediWound Ltd. (NASDAQ:MDWD) were released by: Globenewswire.com and their article: “MediWound Further Expands NexoBrid’s® Global Outreach through New Distribution …” published on October 16, 2017 as well as Globenewswire.com‘s news article titled: “MediWound Successfully Completes Second Cohort of EscharEx® Phase 2 Study” with publication date: September 01, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter: